Metabolic issues contain impaired glucose and lipid homeostasis, insulin resistance, power low-grade irritation, and mitochondrial dysfunction, all of which contribute to the event of kind 2 diabetes mellitus and associated cardiometabolic problems. Latest proof emphasises mitochondrial signaling as a key regulator of mobile vitality steadiness and metabolic flexibility, positioning it as a promising therapeutic goal. Chrysin, a naturally occurring flavone discovered abundantly in honey, propolis, and varied medicinal vegetation, has attracted curiosity for its metabolic regulatory properties in preclinical research. This mechanistic evaluate critically examines experimental proof on how chrysin influences metabolic issues by mitochondrial signaling pathways. Preclinical research show that chrysin improves mitochondrial bioenergetics by enhancing oxidative phosphorylation effectivity, ATP technology, and mitochondrial biogenesis, whereas concurrently lowering extreme reactive oxygen species manufacturing. Chrysin has been proven to activate key energy-sensing pathways, together with AMP-activated protein kinase and downstream regulators, thereby selling glucose uptake, suppressing hepatic gluconeogenesis, and enhancing insulin sensitivity in peripheral tissues. Moreover, chrysin-mediated modulation of mitochondrial dynamics and antioxidant defence techniques contributes to the attenuation of irritation and lipid accumulation. In adipose and hepatic tissues, these results translate into improved lipid metabolism, decreased free fatty acid launch, and normalisation of metabolic enzyme expression. Collectively, the out there preclinical proof helps chrysin as a multi-target metabolic modulator appearing by mitochondrial signaling networks.
Key phrases:
AMP-activated protein kinase; Chrysin; Insulin resistance; Metabolic dysfunction; Mitochondrial signaling; Oxidative stress.
